Please assess the completion status of the following clinical trial:

Trial Title: OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~-Patients with symptoms of Overactive Bladder (OAB) (frequency and urgency) with urinary incontinence for at least 6 months prior to screening.~Exclusion Criteria:~* Symptoms of OAB due to a neurological reason~* Use of anticholinergics or other medications or therapies to treat symptoms of OAB within 7 days of screening~* Use of Clean Intermittent Catheterization (CIC) or indwelling catheter to manage urinary incontinence~* Use of botulinum toxin therapy of any serotype for any urological condition~* Use of botulinum toxin therapy of any serotype for any non-urological condition in the 12 weeks prior to screening~* History of any pelvic or urological abnormalities, bladder surgery or disease, other than OAB, that may affect bladder function~* Diagnosis of Myasthenia gravis, Eaton-Lambert syndrome, or Amyotrophic Lateral Sclerosis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OnabotulinumtoxinA (Type: EXPERIMENTAL): OnabotulinumtoxinA (BOTOX®) 100U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100U after a minimum of 12 weeks (if applicable).
- Placebo/OnabotulinumtoxinA (Type: OTHER): Placebo (Normal saline) injected into the detrusor on Day 1, followed by an injection of onabotulinumtoxinA 100U after a minimum of 12 weeks (if applicable).

Based on this trial design, predict the completion outcome and termination type (if applicable).